arrow
S

Soo Aleman

Hospital Clínic de Barcelona
H指数:42
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Progression to cirrhosis in chronic hepatitis D with mild-to-moderate fibrosis: Insights from a multicenter European cohort (vol 8, 101898, 2026)

慢性丁型肝炎伴轻度至中度纤维化进展为肝硬化的进程:来自多中心欧洲队列的见解(卷8,101898,2026)

2026-09-010
OA
Hepatic flares, their immune signatures, and ALT variability after nucleos(t)ide analogue cessation in HBeAg-negative hepatitis B

HBeAg阴性乙型肝炎患者核苷(酸)类似物停药后的肝功能flare、免疫特征及ALT变异性

2026-06-011
OA
Diabetes, male sex, low levels of HBsAg, HDV RNA, and ALT predict spontaneous HDV suppression in chronic hepatitis D

糖尿病、男性、HBsAg水平低、HDV RNA和ALT水平低预测慢性丁型肝炎中丁型肝炎病毒的自主抑制

2026-05-010
PRE
144 Weeks of bulevirtide monotherapy for chronic hepatitis D: Final and posttreatment results from a Phase 3 randomized trial

144周布罗维特德单药治疗慢性丁型肝炎:一项III期随机试验的最终和治疗后结果

2026-04-090
PRE
Prevalence and Risk Factors of Elevated Alanine Aminotransferase (ALT) in 2382 Treatment-naïve HBV/HDV Co-Infected Patients

2382例HBV/HDV合并感染初治患者中丙氨酸氨基转移酶(ALT)升高的患病率及危险因素

2026-02-260
OAAI
The impact of B-cell reconstitution on mRNA vaccine responses in allogeneic stem cell transplant recipients

B细胞重建对异基因干细胞移植受者mRNA疫苗应答的影响

2026-02-110
OAAI
Corrigendum to “Sociodemographic factors influencing SARS-CoV-2 vaccination uptake in people with and without HIV: Insights from a Swedish Nationwide cohort” [Vaccine 62 (2025) 127580]

勘误:“Sociodemographic factors influencing SARS-CoV-2 vaccination uptake in people with and without HIV: Insights from a Swedish Nationwide cohort” [Vaccine 62 (2025) 127580]

Vaccine
IF3.5
2025-10-170
OAAI
Identification of soluble biomarkers that associate with distinct manifestations of long COVID

鉴定与长COVID不同表现相关联的可溶性生物标志物

2025-04-301
OA
Outcomes of the COVID-19 pandemic in chronic lymphocytic leukemia: focus on the very early period and Omicron era

COVID-19大流行在慢性淋巴细胞白血病中的结局:聚焦于极早期阶段和Omicron时代

2025-02-250
OA
Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48
2024-12-081
OAAI